ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
申请人:Leivers Martin Robert
公开号:US20090226398A1
公开(公告)日:2009-09-10
Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
[EN] DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS<br/>[FR] DÉRIVÉS D'IMIDAZO[4,5-D]PYRIDAZINE ET LEUR UTILISATION EN TANT QUE COMPOSÉS ANTIVIRAUX
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2009111501A1
公开(公告)日:2009-09-11
Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism
作者:Martin Leivers、John F. Miller、Stephanie A. Chan、Ryan Lauchli、Sebastian Liehr、Wenyan Mo、Tony Ton、Elizabeth M. Turner、Michael Youngman、J. Greg Falls、Susan Long、Amanda Mathis、Jill Walker
DOI:10.1021/jm401337x
日期:2014.3.13
By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.